Rituximab maintenance therapy for patients with diffuse large B-cell lymphoma: A meta-analysis

about

Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy.

P2860

Q55283747-1740DE3F-F3BE-4A8F-859A-1E14B577F551

P2860

Rituximab maintenance therapy for patients with diffuse large B-cell lymphoma: A meta-analysis

Item

http://www.wikidata.org/entity/Q36326867

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Rituximab maintenance therapy ...... cell lymphoma: A meta-analysis

@ast

Rituximab maintenance therapy ...... cell lymphoma: A meta-analysis

@en

type

Item

label

Rituximab maintenance therapy ...... cell lymphoma: A meta-analysis

@ast

Rituximab maintenance therapy ...... cell lymphoma: A meta-analysis

@en

prefLabel

Rituximab maintenance therapy ...... cell lymphoma: A meta-analysis

@ast

Rituximab maintenance therapy ...... cell lymphoma: A meta-analysis

@en

P1476

Rituximab maintenance therapy ...... cell lymphoma: A meta-analysis

@en

P2093

Juan Li

http://www.w3.org/2001/XMLSchema#string

Na Zhou

http://www.w3.org/2001/XMLSchema#string

Tingting Ma

http://www.w3.org/2001/XMLSchema#string

Yichan Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Rituximab treatment strategy for patients with diffuse large B-cell lymphoma after first-line therapy: a systematic review and meta-analysis

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

Follow-up of patients receiving rituximab for diffuse large B cell lymphoma: an overview of systematic reviews.

Rituximab in the treatment of B-cell non-Hodgkin lymphoma, focus on outcomes and comparative effectiveness.

Updated survival analysis of two sequential prospective trials of R-MACLO-IVAM followed by maintenance for newly diagnosed mantle cell lymphoma.

Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial.

Rituximab in lymphoma: a systematic review and consensus practice guideline from Cancer Care Ontario.

Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma

New developments in the management of diffuse large B-cell lymphoma.

P304

e0174648

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1371/JOURNAL.PONE.0174648

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Xuan Zhou

P577

2017-03-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28355276

http://www.w3.org/2001/XMLSchema#string

P932

5371376

http://www.w3.org/2001/XMLSchema#string

Rituximab maintenance therapy for patients with diffuse large B-cell lymphoma: A meta-analysis

about

P2860

P2860

Rituximab maintenance therapy for patients with diffuse large B-cell lymphoma: A meta-analysis

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932